Roel Bulthuis Overview
- Firm
- Syncona
- Primary Position
-
Managing Partner...
- Primary Industry
-
Healthcare
- Active Board Seats
-
3
- Med. Deal Size
-
- Med. Valuation
-
Roel Bulthuis General Information
Biography
Mr. Roel Bulthuis serves as Managing Partner & Head of Investments at Syncona. He served as Board Member at Comet Therapeutics. He serves as a Board Member at Draupnir Bio & tincture. He served as a Board Member at VarmX. He served as a Board Member at Canbex Therapeutics and Calypso Biotech. He served as a Board Member at Salvia BioElectronics. He also served as a Venture Advisor at The Founders Club. He served as Managing Director at Inkef Capital. He served as a Board Member at QurAlis and Scenic Biotech. He also founded and served as Senior Vice President and Managing Director of Merck Ventures. He joined the biopharmaceutical division of Merck KGaA, Darmstadt, Germany in 2006 and started MS Ventures in 2009. Previously, he was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, he worked at Devgen NV in Gent, Belgium, as a business analyst. He holds an MSc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.
Contact Information
Address
- 2nd Floor
- 8 Bloomsbury Street
- London WC1B 3SR
- England, United Kingdom
Roel Bulthuis Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Syncona | Investor | Managing Partner & Head of Investments | London, United Kingdom | Venture Capital |
Roel Bulthuis Board Seats (3)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Draupnir Bio | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Copenhagen, Denmark | |
iOnctura | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Genève, Switzerland | |
NMD Pharma | Biotechnology | Privately Held (backing) | Venture Capital-Backed | Aarhus N, Denmark |
Roel Bulthuis Lead Partner on Deals (22)
Roel Bulthuis has been the lead partner on 22 deals. Their latest deal was with iOnctura, a drug discovery company. The deal was made for on 20-Jun-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
iOnctura | 20-Jun-2024 | Later Stage VC (Series B) | Completed | Drug Discovery | Genève, Switzerland | |
VarmX | 25-May-2023 | Completed | Drug Discovery | Leiden, Netherlands | ||
QurAlis | 09-Mar-2023 | Completed | Biotechnology | Cambridge, MA | ||
Scenic Biotech | 10-Mar-2022 | Completed | Drug Discovery | Amsterdam, Netherlands | ||
NMD Pharma | 15-Feb-2022 | Completed | Biotechnology | Aarhus N, Denmark | ||
InteRNA Technologies | 09-Feb-2021 | Completed | Drug Discovery | Utrecht, Netherlands | ||
Salvia BioElectronics | 22-Sep-2020 | Completed | Therapeutic Devices | Eindhoven, Netherlands | ||
VarmX | 03-Jul-2020 | Completed | Drug Discovery | Leiden, Netherlands | ||
QurAlis | 13-May-2020 | Early Stage VC (Series A1) | Completed | Biotechnology | Cambridge, MA | |
Draupnir Bio | 01-Oct-2019 | Early Stage VC (Series A) | Completed | Drug Discovery | Copenhagen, Denmark |
Roel Bulthuis Network (292)
Board Members (138)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Andrew McLean MD | Scenic Biotech | Oxford Science Enterprises | Amsterdam, Netherlands | |
Stéphane Verdood | Scenic Biotech | Vesalius Biocapital Partners | Amsterdam, Netherlands | |
F-Star Therapeutics | Self | Cambridge, United Kingdom | ||
QurAlis | Sanofi Ventures | Cambridge, MA | ||
NMD Pharma | Roche Venture Fund | Aarhus N, Denmark |
Portfolio Executives (143)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
David Seeberger | iOnctura | Chief Financial Officer | 20-Jun-2024 | Genève, Switzerland |
Michael Lahn | iOnctura | Chief Medical Officer | 20-Jun-2024 | Genève, Switzerland |
iOnctura | Co-Founder, CSO & Board Member | 20-Jun-2024 | Genève, Switzerland | |
iOnctura | Co-Founder, Chief Executive Officer & Board Member | 20-Jun-2024 | Genève, Switzerland | |
iOnctura | Member of Scientific Advisory Board | 20-Jun-2024 | Genève, Switzerland |
Fund Team Members (11)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Nilesh Kumar Ph.D | M Ventures | Merck Serono Entrepreneur Partnership Program | Amsterdam, Netherlands |
Nilesh Kumar Ph.D | M Ventures | Merck Serono Israel BioIncubator Fund | Amsterdam, Netherlands |
M Ventures | Amsterdam, Netherlands | ||
M Ventures | Amsterdam, Netherlands | ||
M Ventures | Amsterdam, Netherlands |
Roel Bulthuis Affiliated Funds (4)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Merck Serono Entrepreneur Partnership Program | M Ventures | Venture - General | Closed | 2013 | ||||
Inkef Fund | Inkef | Venture Capital - Early Stage | Closed | 2007 | ||||
Merck Serono Israel BioIncubator Fund | M Ventures | Venture Capital - Early Stage | Closed | 2011 | ||||
M Ventures Healthcare | M Ventures | Venture - General | Evergreen |
Roel Bulthuis FAQs
-
Who is Roel Bulthuis?
Mr. Roel Bulthuis serves as Managing Partner & Head of Investments at Syncona.
-
How much does Roel Bulthuis typically invest?
Roel Bulthuis's median deal size is
. -
What is Roel Bulthuis’s main position?
Roel Bulthuis’s primary position is Managing Partner & Head of Investments.
-
What are the contact details for Roel Bulthuis?
Roel Bulthuis’s email address is r.
and his phone number is +44 020 . -
How many active board seats does Roel Bulthuis hold?
Roel Bulthuis holds 3 board seats including Draupnir Bio, iOnctura, and NMD Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »